Editas Medicine (EDIT) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Editas Medicine

NasdaqGS•Healthcare•Biotechnology

$3.23+0.15(0.05%)Market closed

Market Cap

$324.48M

P/S

6.9x

P/B

3.1x

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

How this company scores

WeakMetricSide Score: 61/100

Grade capped at D — Interest coverage below 1× (-17.9x) — earnings cannot cover interest. Strongest: Growth (19/25); weakest: Cash & Earnings Quality (10/25).

Profitability15/25

Growth19/25

Balance Sheet & Red Flags17/25

Cash & Earnings Quality10/25

Strengths

Growing revenueLow leverageCash-backed earningsProfit converts from growth

Grade capped at D

Interest coverage below 1× (-17.9x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 6.9x5y range 2.7x – 118.4x

Currently below its 20-quarter median.

P/B · 3.1x5y range 0.7x – 49.5x

Currently above its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $324.48M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $47.01M
Q. Revenue: $11.89M
TTM EBITDA: $-73.44M
TTM Op. Income: $-75.86M
Q. Op. Income: $-18.55M
TTM Net Income: $-73.95M
Q. Net Income: $-18.23M
EPS: $-0.15
Shares Out.: $119.29M

$47.01M in TTM revenue grew 20.8% YoY, reaching $11.89M last quarter. TTM EBITDA of $-73.44M and TTM operating income of $-75.86M show growth is flowing through to the bottom line. However, net income is negative at $73.95M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is up 21% — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -152.5%
Op. Margin: -156.0%
Net Margin: -153.3%

Op. margin of -156.0% is up 1284.5% YoY — cost efficiency is improving. Net margin at -153.3% Over the past year, operating margin is up 89% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 6.9x
P/B Ratio: 3.1x

P/S of 6.9x and P/B of 3.1x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $237.36M
Cash: $181.81M
Long-Term Debt: $48.24M
Book Value: $105.28M
D/E Ratio: 0.5
Debt/EBITDA: N/A

With $237.36M in assets and $48.24M in long-term debt, D/E is 0.5and book value is $105.28M — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is down 83% — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-29.57M
TTM Free Cash Flow: $-120.55M
FCF Margin: -256.5%
FCF / Net Income: 1.6

TTM FCF of $-120.55M on $-29.57M in operating cash flow. The FCF / Net Income ratio of 1.6x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 6 consecutive quarters — an improving trend.